NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Long-term Safety of VAXZEVRIA

CompletedN/A

Sponsor: AstraZeneca

Conditions: Prevention of Infectious Disease Caused by SARS-CoV-2

Countries: Japan

This survey will be conducted for the subjects who participate in the priority survey (cohort survey) conducted by the Scientific Research Group of the Ministry of Health, Labour and Welfare at the initial stage of administration of the COVID-19 vaccination. The present study aims to collect information on serious adverse events or COVID-19 infection observed from 28 days after the last vaccination of VAXZEVRIA up to 12 months after the last vaccination and to evaluate the long-term safety of this vaccine.

Eligibility overview

Sex: ALL

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

The subjects who participated in the cohort study conducted by the Scientific Research Group of the MHLW and those who give written consents for this study.

Exclusion Criteria:

None

Locations (6)

Chiba, Japan
Hyōgo, Japan
Kumamoto, Japan
Mie, Japan
Shizuoka, Japan
Tokyo, Japan